Study | Country | Study type | Sample size (intervention/control) | Age(Mea ± SD) | Type and duration of supplementation | Primary outcomes | |||
---|---|---|---|---|---|---|---|---|---|
Intervention group | Placebo group | Chronic pelvic pain | Dysmenorrhea | Dyspareunia | |||||
Nalini Santanam et al.,2013 [29] | Atlanta | RCT | (46/13) | 19-41year | vitaminE1200IU + vitamin C1000mg for 8 weeks | placebo pills daily for 8 weeks | Intervention group patient with decreased pain (43%) Control group patient with decreased pain (0%) | Intervention group patient with decreased pain (37%) Control group patient with decreased pain (36%) | Intervention group patient with decreased pain (24%) Control group patient with decreased pain(0%) |
Ibrahim Abd El-Fadil Sehsah et al.;2022 [30] | Egypt | RCT | (50/50) | Intervention: 25.36 ± 3.75; Control: 26.18 ± 4.24 | vitamin E 1200mg/day and vitamin C 1000mg/day for 6–8 weeks | placebo for 6–8 weeks | Intervention group patient with decreased pain (48%) Control group patient with decreased pain(10%) | Intervention group patient with decreased pain (48%) Control group patient with decreased pain(10%) | Intervention group patient with decreased pain (32%) Control group patient with decreased pain(8%) |
Mahmoud A. Al-Naggar et al.;2022 [31] | Iran | RCT | (30/30) | Intervention: 32.5 ± 4.5 Control: 31.4 ± 5.2 | vitaminE1200IU/day +  Vitamin C 1000mg/day for 8 weeks | Placebo pills for 8 weeks | Intervention group patient with decreased pain (30%) Control group patient with decreased pain(0%) | Intervention group patient with decreased pain(26.6%) Control group patient with decreased pain(0%) | Intervention group patient with decreased pain (16.6%) Control group patient with decreased pain(0%) |
Leila Amini et al,2021 [32] | Iran | RCT | (30/30) | Intervention: 35.7 ± 5.71; Control: 38.03 ± 6.47 | vitaminE800IU + vitaminC1000mg for 8 weeks | placebo pills daily for 8 weeks | Intervention VAS score: pre-post: (66.26 ± 27.84– 12.43 ± 13.28) Control group VAS score :pre-post: (16.96 ± 16.28– 18.63 ± 18.35);P < 0.001 | Intervention VAS score: pre-post: (50.53 ± 32.12–17.56 ± 16.65) Control group VAS scorec: pre-post: (51.00 ± 34.21– 31.56 ± 26.39);P < 0.001 | Intervention VAS score pre-post: (66.26 ± 28.27– 15.43 ± 18.47) Control group VAS score: pre-post: (20.73 ± 21.77– 18.10 ± 19.93);P < 0.001 |
HuiMing Wang 2017 [33] | China | RCT | (32/32) | Intervention: 37.9 ± 3.5; Control: 35.0 ± 3.3 | Yasmin + vitamin E 100mg/d for 6mo | Yasmin for 6mo | Intervention VAS score: pre-post: 7.85 ± 2.17- 2.65 ± 0.81; Control group VAS score: pre-post:7.90 ± 1.19—4.35 ± 1.11 | Intervention VAS score: pre-post:6.75 ± 1.25–2.50 ± 1.00; Control group VAS score: pre-post:6.63 ± 1.27 –2.79 ± 1.21 | Intervention VAS score: pre-post: 7.73 ± 2.15–3.01 ± 1.11; Control group VAS score: pre-post:7.65 ± 1.20–3.13 ± 1.01 |
Xiao Jing et al. 2018 [34] | China | RCT | (30/30) | Intervention: 35.12 ± 3.2; Control: 38.02 ± 4.01 | Yasmin + vitamin E 100mg/d for 6mo | Yasmin for 6mo | Intervention VAS score: pre-post:7.83 ± 2.16–2.66 ± 0.82; Control group VAS score: pre-post: 7.81 ± 0.82–4.33 ± 1.10 | Intervention VAS score: pre-post:6.77 ± 1.24–2.51 ± 1.02; Control group VAS score: pre-post: 6.62 ± 1.28–2.80 ± 1.20 | Intervention VAS score: pre-post:7.72 ± 2.14–3.00 ± 1.12; Control group VAS score: pre-post: 7.66 ± 1.21–3.12 ± 1.02 |
Hu Yan et al. 2015 [35] | China | RCT | (26/25) | Intervention: 32.45 ± 6.18; Control: 34.62 ± 5.47 | Yasmin + vitamin E 100mg/d for 6mo | Yasmin for 6mo | Intervention VAS score: pre-post:74.05(16.17)-30.14(15.29); Control group VAS score: pre-post:76.11(17.84)-51.37(13.54) | Intervention VAS score: pre-post:77.27(16.46) –42.33(10.15); Control group VAS score: pre-post:75.28(16.54)–44.08(12.80) | Intervention VAS score: pre-post:68.36(19.08)-50.41(13.78); Control group VAS score: pre-post:65.61(17.14)-49.24(12.63) |
Fariba Almassinokiani et al.; 2016 [23] | Iran | RCT | (19/19) | Intervention:30.84 ± 5.79 Control: 28.95 ± 4.71 | vitamin D 3(50 000 IU weekly for 12 weeks | placebo for 12 weeks | Intervention VAS score: pre-post:4.05 (3.45)–0.84 (1.74); Control group VAS score: pre-post: 4.82 (4.1) –0.68 (1.70) | Intervention VAS score: pre-post: 7.37 (2.61)–2.10 (2.33); Control group VAS score: pre-post:6.42 (3.04)–2.73 (2.84) |  |
Abolfazl Mehdizadehkashi et al.;2021 [24] | Germany | RCT | (25/25) | Intervention: 34.8 ± 7.1; Control: 35.6 ± 7.0 | 50,000 IU vitamin D every 2 weeks for 12 weeks | placebo for 12 weeks |  | Intervention VAS score: pre-post: (8.0 ± 1.8– 4.8 ± 1.7) Control group VAS score: pre-post: ( 6.8 ± 2.6– 4.9 ± 2.8); | Intervention VAS score: pre-post: ( 6.1 ± 2.6–3.8 ± 2.3) Control group VAS score: pre-post: (7.3 ± 2.5– 5.2 ± 2.6); |
James L Nodler et al.; 2020 [36] | America | RCT | (27/20) | Intervention: 20.0 ± 2.7; Control: 20.1 ± 3.5 | 2000 IU vitamin D3 for 6mo | placebo for 6 mo | Intervention VAS score: pre-post:7.0 (2.2)– 5.5(3.1); Control group VAS score: pre-post 6.0 (1.9)- 4.4 (3.1) |  |  |